eversyn

We have developed a production platform to make activated sugars at a fraction of the current costs…
...which we use as the building blocks for complex Human Milk Oligosaccharides for infant formula and nutritional supplements
…as well as for tailoring glycosylation of therapeutic proteins for more efficient
biobetters and biosimilars.

Upon request.

The high cost and availability of activated sugars are the bottlenecks in
the production of HMOs & the glycosylation of antibodies.
#1. TECHNICAL FEASIBILITY
The current technology for synthesizing HMOs is not established yet, especially for complex longer chains.
#2. HIGH COST
The building blocks are still prohibitively expensive for the commercialization of many HMOs and tailoring glycosylation of therapeutic proteins.
#3. LOW SCALABILITY
Ultimately, the cost factors prohibit the upscaling from mass production &
commercialization.

eversyn is setting new precedents in enzymatic carbohydrate synthesis
We have developed a production platform to make activated sugars at a fraction of the current costs…
…which we use as the building blocks for complex Human Milk Oligosaccharides for infant formula and nutritional supplements…
…as well as for tailoring glycosylation of therapeutic proteins for more efficient
biobetters and biosimilars.

Upon requests.

- Scalability
- High Affordability
- IP protection
- Backed by years of world-class research from Max Planck Society

R&D (Setting up labs, buying equipment...)
Salary for personnel
G&A
Outsourcing